Literature DB >> 10427163

Human mammary gland and breast carcinoma contain immunoreactive inhibin/activin subunits: evidence for a secretion into cystic fluid.

C Di Loreto1, F M Reis, P Cataldi, C Zuiani, S Luisi, C A Beltrami, F Petraglia.   

Abstract

OBJECTIVE: Inhibins and activins are members of the transforming growth factor beta superfamily and are known to modulate the growth and differentiation of several cell types. The present study investigated the localization of inhibin and activin subunits in human normal and pathological breast tissues.
DESIGN: A cross-sectional study comparing the expression of inhibin/activin subunits alpha, betaA and betaB in surgical specimens from women undergoing reductive mammoplasty (classified, according to the phase of the menstrual cycle, as follicular, luteal, or postmenopausal), and patients submitted to lumpectomy for fibrocystic disease, benign (intraductal papilloma, adenomyoepithelioma, and hamartoma) or malignant breast neoplams (intraductal, intralobular, and invasive carcinoma).
METHODS: Immunohistochemistry was used to localize inhibin alpha and activin betaA and betaB subunits in the cytoplasm of epithelial cells of mammary glands. Dimeric activin A, inhibin A and inhibin B were measured by specific two-site enzyme immunoassay in the cystic fluid collected from patients with fibrocystic disease.
RESULTS: An intense staining for the alpha inhibin subunit and a mild staining for betaA and betaB subunits were present in samples obtained from normal breast tissue regardless of menstrual cycle phase, and in fibrocystic disease and benign neoplasms. Carcinoma cells stained weakly to moderately for alpha subunit and were negative for betaA and betaB subunits. Fibrocystic disease was associated with absence of betaA subunit expression in normal epithelial cells and intense staining for all subunits in the apocrine cells. Immunoreactive inhibin A, inhibin B, and activin A were also present in cystic fluid, suggesting a local secretion of these proteins.
CONCLUSION: These data suggest a local expression and secretion of inhibin and activin in human normal, fibrocystic disease and neoplastic breast tissues. The low expression of these proteins may facilitate abnormal cell proliferation in breast carcinoma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10427163     DOI: 10.1530/eje.0.1410190

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  8 in total

Review 1.  The role of activin in mammary gland development and oncogenesis.

Authors:  Karen A Dunphy; Alan L Schneyer; Mary J Hagen; D Joseph Jerry
Journal:  J Mammary Gland Biol Neoplasia       Date:  2011-04-08       Impact factor: 2.673

Review 2.  Inhibin at 90: from discovery to clinical application, a historical review.

Authors:  Yogeshwar Makanji; Jie Zhu; Rama Mishra; Chris Holmquist; Winifred P S Wong; Neena B Schwartz; Kelly E Mayo; Teresa K Woodruff
Journal:  Endocr Rev       Date:  2014-07-22       Impact factor: 19.871

Review 3.  Benign breast diseases.

Authors:  Carine Courtillot; Geneviève Plu-Bureau; Nadine Binart; Corinne Balleyguier; Brigitte Sigal-Zafrani; Vincent Goffin; Frédérique Kuttenn; Paul A Kelly; Philippe Touraine
Journal:  J Mammary Gland Biol Neoplasia       Date:  2005-10       Impact factor: 2.673

Review 4.  The Activin Social Network: Activin, Inhibin, and Follistatin in Breast Development and Cancer.

Authors:  Darcie D Seachrist; Ruth A Keri
Journal:  Endocrinology       Date:  2019-05-01       Impact factor: 4.736

5.  The immunoexpressions and prognostic significance of inhibin alpha and beta human chorionic gonadotrophins (HCG) in breast carcinomas.

Authors:  Eundeok Chang; Eunjung Lee; Se Jeong Oh; Jeong Soo Kim; Changsuk Kang
Journal:  Cancer Res Treat       Date:  2005-08-31       Impact factor: 4.679

6.  Effect of keratinocyte growth factor and activin on cell growth in the human prostatic cancer cell line LNCaP.

Authors:  Bernhard Planz; Horia Oltean; Thomas Deix; Sandra D Kirley; Qi Fa Wang; W S McDougal; Michael Marberger
Journal:  World J Urol       Date:  2004-02-27       Impact factor: 4.226

7.  Growth factor genes and change in mammographic density after stopping combined hormone therapy in the California Teachers Study.

Authors:  Eunjung Lee; Jianning Luo; Fredrick R Schumacher; David Van Den Berg; Anna H Wu; Daniel O Stram; Leslie Bernstein; Giske Ursin
Journal:  BMC Cancer       Date:  2018-11-06       Impact factor: 4.430

8.  Differential expression of follistatin and FLRG in human breast proliferative disorders.

Authors:  Enrrico Bloise; Henrique L Couto; Lauretta Massai; Pasquapina Ciarmela; Marzia Mencarelli; Lavinia E Borges; Michela Muscettola; Giovanni Grasso; Vania F Amaral; Geovanni D Cassali; Felice Petraglia; Fernando M Reis
Journal:  BMC Cancer       Date:  2009-09-09       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.